If you read the article it says that...: "For AbbVie, the rationale for the acquisition is clear – expand the portfolio and preserve the bottom line ahead of Humira’s patent expiration in the U.S. in 2023. Several of AbbVie’s experimental drug hopefuls have hit hitches in the past year, and Humira has already faced increased competition in markets like Europe."
...." the AbbVie Allergan deal isn’t just a story about health care consolidation – it’s one about the state of innovation among big, legacy biopharma companies scurrying to find ways to plug future holes in their revenue streams. Both companies have bled market value in the past year as investors questioned whether AbbVie can make up for falling sales of its blockbuster psoriasis and arthritis treatment Humira, which rang in nearly $20 billion in 2018 revenues alone, and pushed for a breakup of Allergan amid pipeline struggles."
How can that be bad for BOT when its products pipeline has the potential to take a big chunk out of their sales?
- Forums
- ASX - By Stock
- BOT
- Bot Chart
Bot Chart, page-577
-
- There are more pages in this discussion • 13,172 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
38.0¢ |
Change
0.055(16.9%) |
Mkt cap ! $687.8M |
Open | High | Low | Value | Volume |
33.0¢ | 38.0¢ | 33.0¢ | $7.103M | 19.63M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 134000 | 37.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.0¢ | 650314 | 19 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 132500 | 0.375 |
3 | 7752 | 0.370 |
2 | 24000 | 0.365 |
1 | 4166 | 0.360 |
3 | 59669 | 0.355 |
Price($) | Vol. | No. |
---|---|---|
0.380 | 502144 | 15 |
0.385 | 164500 | 4 |
0.390 | 276986 | 11 |
0.395 | 750000 | 5 |
0.400 | 660032 | 20 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |